The stock of Avantor Inc. (NYSE:AVTR) last traded at $18.56, up 0.92% from the previous session.
Data from the available sources indicates that Avantor Inc. (NYSE:AVTR) is covered by 22 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $30.00 and a low of $18.00, we find $22.75. Given the previous closing price of $18.39, this indicates a potential upside of 23.71 percent. AVTR stock price is now -8.78% away from the 50-day moving average and -12.18% away from the 200-day moving average. The market capitalization of the company currently stands at $12.55B.
In total, 7 analysts have assigned it a hold rating, and 12 have given it a buy rating. Brokers who have rated the stock have averaged $22.99 as their price target over the next twelve months.
With the price target of $22, Bernstein recently initiated with Mkt Perform rating for Avantor Inc. (NYSE: AVTR).
In other news, Eck Steven W, SVP & Chief Accounting Officer sold 7,577 shares of the company’s stock on Sep 07. The stock was sold for $156,389 at an average price of $20.64. Upon completion of the transaction, the SVP & Chief Accounting Officer now directly owns 28,187 shares in the company, valued at $0.52 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 25, EVP, Americas and Europe Vanderhaegen Frederic sold 25,000 shares of the business’s stock. A total of $536,750 was realized by selling the stock at an average price of $21.47. This leaves the insider owning 160,735 shares of the company worth $2.98 million. Insiders disposed of 548,848 shares of company stock worth roughly $10.19 million over the past 1 year. A total of 2.56% of the company’s stock is owned by insiders.
With an opening price of $18.39 on Friday morning, Avantor Inc. (NYSE: AVTR) set off the trading day. During the past 12 months, Avantor Inc. has had a low of $16.63 and a high of $25.25. As of last week, the company has a debt-to-equity ratio of 1.10, a current ratio of 1.60, and a quick ratio of 1.03. According to the stock market information, the enterprise value for the company is $17.94B, which is based on a 34.54 price-to-earnings ratio, a 1.54 price-to-earnings-growth ratio, and a beta of 1.31. The fifty day moving average price for AVTR is $20.29 and a two-hundred day moving average price translates $21.11 for the stock.
The latest earnings results from Avantor Inc. (NYSE: AVTR) was released for Sep, 2023. According to the Specialty Chemicals Company, earnings per share came in at $0.28, missing analysts’ expectations of $0.29 by -0.01. This compares to $0.25 EPS in the same period last year. The net profit margin was 5.18% and return on equity was 7.52% for AVTR. The company reported revenue of $1.72 billion for the quarter, compared to $1.86 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -7.34 percent. For the current quarter, analysts expect AVTR to generate $1.71B in revenue.
Avantor Inc.(AVTR) Company Profile
Avantor, Inc. engages in the provision of mission-critical products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides logistics, chemical and equipment tracking, and glassware autoclaving, as well as scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.